Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial)

China Nagano(Broad Institute), Kazumoto Iijima(Kobe Children's Hospital), Koichi Nakanishi(University of the Ryukyus), Kenji Ishikura(Kitasato University), Koichi Kamei(National Center For Child Health and Development), Takashi Omori(Kyoto University), Kandai Nozu(Kobe Children's Hospital), Mayumi Sako(National Center For Child Health and Development), Hidefumi Nakamura(National Center For Child Health and Development)
BMC Nephrology
August 2, 2019
10.1186/s12882-019-1470-3
Cited by 19

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|278
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease
|Clinical and Experimental Nephrology|2013|267
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
|Pediatric Nephrology|2021|149
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
|Kidney International|2014|135